D.C. Lung Cancer Conference 2026


D.C. Lung Cancer Conference 2026 Banner

Add to Calendar D.C. Lung Cancer Conference 2026 10/10/2026 7:00:00 AM 10/10/2026 9:00:00 PM America/New_York For More Details: https://medstar.cloud-cme.com/course/courseoverview?EID=48248 Description: This one-day multidisciplinary conference will provide a comprehensive update on recent clinical advances in lung cancer. The field is evolving very rapidly and over the past few years, there have been major shifts in our understanding of this highly lethal disease. We have seen high impact advances in all aspects of lung cancer management: from detection to diagnosis to treatment. The D.C. Lung Canc... JW Marriott false MM/DD/YYYY


Date & Location
Saturday, October 10, 2026, 7:00 AM - 9:00 PM, JW Marriott, Washington, DC

Target Audience
Specialties - Internal Medicine, Medical Oncology, Oncology, Pathology, Pulmonology, Radiation Oncology, Radiology, Surgery
Professions - Non-Physician, Nurse, Nurse Practitioner, Pharmacist, Physician, Student

Overview
This one-day multidisciplinary conference will provide a comprehensive update on recent clinical advances in lung cancer. The field is evolving very rapidly and over the past few years, there have been major shifts in our understanding of this highly lethal disease. We have seen high impact advances in all aspects of lung cancer management: from detection to diagnosis to treatment. The D.C. Lung Cancer Conference will emphasize current best practices for busy clinicians who care for patients with lung cancer, across disciplines. High impact, engaging didactic lectures will be delivered by international thought leaders and well-respected faculty in each field. An opening talk from a patient advocate will provide an important perspective. There will be updates on CT screening, proper use of liquid biopsy, interpretation of molecular testing results and review of smoking cessation techniques. A section will be dedicated to optimizing multidisciplinary care for early stage and locally advanced lung cancer to include discussions on minimally invasive surgery and both neoadjuvant and adjuvant systemic therapy, including targeted agents and immunotherapy. Additional sessions will discuss the optimal management of specific molecular subsets of lung cancer, highlighting all currently approved agents, and will also highlight rarer thoracic tumors such as thymic malignancies and mesothelioma. Each session will include a detailed case discussion. Attendees will have the opportunity to interact with faculty in frequent Q&A sessions with access to presentation materials for later review.

Objectives
After completing this activity, the participant will be able to:

  1. Identify the survival benefit of CT screening for lung cancer.
  2. Describe the methods used for biomarker testing in lung cancer.
  3. Explain the approved use of neoadjuvant and perioperative immunotherapy for patients with resectable lung cancer.
  4. Debate the approach for a patient with EGFR-mutated NSCLC with borderline resectable NSCLC.
  5. Describe the best initial therapy for advanced small cell lung cancer (SCLC).
  6. Discuss management of immune-mediated toxicities.
  7. Discuss standard targeted agents in use for patients with ALK-positive non-small cell lung cancer.
  8. Explain the approved use of targeted therapy for KRAS-mutant non-small cell lung cancer.
  9. Name the approved targeted agent for HER2 mutant NSCLC.

Registration

Early Bird Rate through June 5

  • Physician $225

  • Resident/Fellow $0

  • Physician Assistant $150

  • Nurse Practitioner $150

  • Nurse $150

  • Allied Health Professional $150

  • Pharmacist $150

  • Industry Professional  $300

Advanced Purchase and Onsite Rate June 6 through October 10

  • Physician $250

  • Resident/Fellow $0

  • Physician Assistant $175

  • Nurse Practitioner $175

  • Nurse $175

  • Allied Health Professional $175

  • Pharmacist $175

  • Industry Professional  $350

Lung Prom Tickets

  • General Ticket $125

Please contact [email protected] or (833) 731-1273 for registration assistance


Accreditation

 In support of improving patient care, MedStar Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

 

Credit Designation Statement

This activity was planned by and for the healthcare team and learners will receive 7.0 Interprofessional Continuing Education (IPCE) credits for learning and change.

 

 

Physicians: MedStar Health designates this live activity for a maximum of 7.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

American Board of Internal Medicine MOC Credit

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 7.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

MOC Participation Threshold

Learner participates by writing a reflective statement and makes a commitment to change or maintain an element of practice.


Nurses: This activity is approved for 7.0 ANCC contact hours, which includes 1.5 pharmacotherapeutic contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacists: This activity is approved for 7.0 contact hours. This learning activity is knowledge-based. The Universal Activity Number for this program is JA4008151-0000-26-052-L05-P.


Credits
AMA PRA Category 1 Credits™ Physician (7.00 hours), ABIM MOC Part 2 (7.00 hours), IPCE (7.00 hours), Non-Physician Member of the Healthcare Team (7.00 hours), Nurse - ANCC (7.00 hours), Pharmacist - ACPE (7.00 hours)